ea0052p14 | (1) | UKINETS2017
Horsch D
, Kulke MH
, Caplin M
, Anthony L
, Bergsland E
, Oberg K
, Warner R
, Kunz P
, Pulido E Grande
, Valle J
, Dillon J
, Lapuerta P
, Banks P
, Jackson S
, Pavel M
Background: The phase III, placebo-controlled, randomized TELESTAR study evaluated efficacy and safety of telotristat ethyl (TE) in patients (pts) with diarrhoea (≥4 bowel movements (BMs)/day) due to carcinoid syndrome (CS) inadequately controlled by somatostatin analogs (SSAs). TE, a tryptophan hydroxylase inhibitor, decreases peripheral serotonin levels. As add-on treatment to SSAs, TE 250 mg 3x/day (tid) and TE 500 mg tid significantly reduced BM frequency (P...